Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110) (EpiCovCreil)

Direction Centrale du Service de Santé des Armées

Status: Completed

Conditions: Sars-CoV2

Treatments: Diagnostic Test: Anti-SARS-CoV2 serological controls and serum neutralization; Behavioral: Questionnaire; Diagnostic Test: Anti-SARS-CoV2 Serology

Study type: Observational

Funder types: Other

Identifiers

NCT04404270

2020-COVID19-22

2020-A01368-31 (Other Identifier)

Details and patient eligibility

About

In mid-February 2020, within the Oise (France) cluster, a case of COVID-19 disease caused by a SARS-CoV2 infection was described among the personnel of the Creail Air Force Base (BA110). This resulted in the beginning of an epidemic controlled by epidemiological measures. One month later, containment measures were taken at the national level, measures that also applied to BA110 personnel. These personnel, exposed to both the initial phase of the epidemic and national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus, particularly at a time when France is lifting the containment measures. It becomes extremely important to understand the levers of viral spread in order to adjust the health measures to be maintained as best as possible.

The main objective of this study is to determine the extent of virus diffusion in this highly circulating population, as evidenced by several identified cases of COVID-19.

Enrollment: 1,146 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Active military or civilian defence personnel working on the Creil Air Force Base (BA110) during the period of interest (from February 1st 2020 to the end of the study)

Exclusion criteria

• Contraindication to blood sampling
• Pregnant, parturient, breastfeeding woman